Zenas BioPharma, Inc. (ZBIO)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-02-13

Key Insights

Zenas BioPharma, Inc. has implemented a new short-term incentive (STI) plan for its employees, effective January 1, 2026, which allows them to earn annual discretionary cash bonuses based on company performance and individual goal achievement.
The STI Plan is administered by the Board of Directors for company executives and by the CEO and executive leadership team for other eligible employees, giving the leadership team flexibility in determining bonus payouts.
The STI Plan includes provisions for clawback and recoupment of incentive compensation, aligning employee incentives with shareholder interests.

Insider Trading Filed: 2026-02-13

Key Insights

The reporting person, Patricia L. Allen, a director of Zenas BioPharma, Inc. (ZBIO), has made multiple open market purchases of the company's common stock totaling 19,860 shares over the past two days.
The purchases were made at prices ranging from $23.77 to $26.50 per share, suggesting the director's confidence in the company's prospects.
The substantial insider buying activity may indicate the director's belief in the company's future growth and potential upside for shareholders.

Insider Trading Filed: 2026-02-13

Key Insights

Hongbo Lu, a director of Zenas BioPharma, Inc., purchased 25,985 shares of the company's common stock at $22.5 per share on February 11, 2026.
The reported securities are owned indirectly by investment funds managed by NEXTBio Capital, and Hongbo Lu is a managing member of the general partners of these funds.
Insider buying can be a positive signal about the company's prospects, as the director is demonstrating confidence in the stock through their personal investment.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.